Omega-3 Enriched Parenteral Emulsion Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional parenteral lipid emulsions rich in long-chain omega-6 fatty acids cause adverse clinical effects such as inflammation, glucose intolerance, and insulin resistance, and are not optimal for intravenous nutrition due to their pro-inflammatory properties.
Innovation Solution
A novel parenteral lipid emulsion composition with a high concentration of omega-3 fatty acids from fish oil triglycerides and a low concentration of medium-chain triglycerides, optionally including omega-6 fatty acids, is developed to minimize adverse effects and provide a stable, effective energy source.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If conventional parenteral lipid emulsions rich in long-chain omega-6 fatty acids are used, then energy provision is achieved, but inflammation and metabolic complications occur
Solution Approach 1:
The patent changes the fatty acid composition parameters by replacing omega-6 fatty acids with omega-3 fatty acids (EPA and DHA) as the primary lipid source. This parameter change transforms the emulsion from pro-inflammatory to anti-inflammatory while maintaining energy provision, directly resolving the contradiction between energy supply and inflammation reduction.
Solution Approach 2:
The patent creates a composite lipid emulsion combining fish oil triglycerides (rich in omega-3 fatty acids) with complementary lipids to achieve both energy density and anti-inflammatory properties. This composite approach allows simultaneous satisfaction of energy requirements and reduction of harmful inflammatory effects.
2Quantity of substance
If conventional parenteral lipid emulsions rich in long-chain omega-6 fatty acids are used, then caloric density is provided, but glucose intolerance and insulin resistance develop
Solution Approach 1:
The patent modifies the lipid composition parameter by substituting omega-6 fatty acids with omega-3 fatty acids, which have been shown to improve insulin sensitivity. This parameter change maintains caloric density while eliminating the harmful effect of insulin resistance associated with omega-6 rich formulations.
3Object-affected harmful factors
If high concentration of omega-3 fatty acids from fish oil is used, then anti-inflammatory effects are achieved, but emulsion stability may be compromised
Solution Approach 1:
The patent formulates a composite emulsion combining fish oil triglycerides (providing anti-inflammatory omega-3 fatty acids) with other lipids that confer emulsion stability. This composite approach allows the simultaneous achievement of anti-inflammatory properties and compositional stability, resolving the contradiction between health benefits and formulation stability.
Data Source
AI summary
An emulsion is provided including: an oil component and a water component, the oil component including: fish oil triglycerides in an amount of about 60% to about 90% based on the weight of the oil component; wherein the fish oil triglycerides include omega-3 fatty acids, expressed as triglycerides, in an amount of at least 60%, based on the total weight of the fatty acids of the fish oil triglycerides; wherein the fish oil triglycerides include a total amount of EPA and DHA, expressed as triglycerides, of at least 45%, based on the total weight of the fatty acids of the fish oil triglycerides; and, at least one medium-chain triglyceride, wherein a total amount of the at least one medium-chain triglyceride is from about 10% to about 40% based on the weight of the oil component.